case_images: PMC10791797_01
case_images: Timeline of different treatments and disease status.
case_images: fimmu-14-1329951-g001.jpg
case_images: PMC10791797_01_fimmu-14-1329951-g001.jpg
case_images: f1
case_images: We show the treatment timeline for the patient in  Figure 1 .
case_images: Interstitial implantation radiotherapy: Three-dimensional conformal dose assessment.
case_images: fimmu-14-1329951-g002.jpg
case_images: PMC10791797_01_fimmu-14-1329951-g002.jpg
case_images: f2
case_images: On December 2, 2022, the patient began immunotherapy with the PD-1 inhibitor tirilizumab (300 mg, ivgtt).  Figure 2  shows the three-dimensional conformal dose assessment for interstitial implantation radiation therapy.
case_images: Changes in lesions: After the triple therapy, the CT showed a significantly smaller pelvic mass. (A) Pelvic mass before the triple therapy. (B) Pelvic mass after the triple therapy.
case_images: fimmu-14-1329951-g003.jpg
case_images: PMC10791797_01_fimmu-14-1329951-g003.jpg
case_images: f3
case_images: As of the follow-up in June 2023, abdominal CT suggested a smaller pelvic mass than before ( Figure 3 ) and CA125 was persistently decreasing (most recent CA125 was 18.30 U/ml) ( Figure 4 ).
case_images: Changes in serum CA125 levels before and after the triple therapy.
case_images: fimmu-14-1329951-g004.jpg
case_images: PMC10791797_01_fimmu-14-1329951-g004.jpg
case_images: f4
case_images: As of the follow-up in June 2023, abdominal CT suggested a smaller pelvic mass than before ( Figure 3 ) and CA125 was persistently decreasing (most recent CA125 was 18.30 U/ml) ( Figure 4 ).